Acquired Immune Deficiency Syndrome



Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Nonnucleoside Reverse Transcriptase Inhibitor Viral Protease Human Immunodeficiency Virus Protease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Arrighi JF, Poin M, Garcia E, Escola JM, et al. 2004. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. JEM. 200:1279–1288. Scholar
  2. Bang LM, Scott LJ. 2003. Emtricitabine: An antiretroviral agent for HIV infection. Drugs. 63:2413–2424.PubMedCrossRefGoogle Scholar
  3. Barreiro P, Rendon A, Rodriguqz-Novoa S, Soriano V. 2005. Atazanavir: the advent of a new generation of more convenient protease inhibitors. HIV Clin Trails. 6:51–60.Google Scholar
  4. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT. et al. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 220:868–871.PubMedCrossRefGoogle Scholar
  5. Berger EA, Murphy PM, Farber JM. 1999. Chemokine receptors as HIV coreceptors: Role in viral entry, tropism and disease. Annu Rev Immunol. 17:657–700.PubMedCrossRefGoogle Scholar
  6. Boshoff C, Weiss R. 2002. AIDS – related malignancies. Nat Rev Cancer 2:373–382.PubMedCrossRefGoogle Scholar
  7. Bradsley-Elliott A, Plosker GL. 2000. Nelfinavir: An update on its use in HIV infection. Drugs. 59:581–620.CrossRefGoogle Scholar
  8. Cao Y, Qin L, Zhang L, Safrit J, et al. 1995. Virologic and immunologic characterization of long term survivors of human immunodeficiency virus type 1 infection. NEJM. 332:201–208.PubMedCrossRefGoogle Scholar
  9. Chan D, Kim P. 1998. HIV entry and its inhibition. Cell. 93:681–684.PubMedCrossRefGoogle Scholar
  10. Chun TW, Engel D, Berrey MM, Shea T. et al. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV infection. Proc Natl. Acad Sci USA. 95:8869–8873Google Scholar
  11. Clotet B, Bellos N, Molina JM, Cooper D, et al. 2007. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomized trials. Lancet. 369:1169–1178.PubMedCrossRefGoogle Scholar
  12. Coffin J, Haase A, Levy A, Montagnier L. et al. 1986. What to call the AIDS virus? Nature 321: 10–10.PubMedGoogle Scholar
  13. Coffin JM. 1995. HIV population dynamics in vivo. Implications for genetic variation, pathogenesis and therapy. Science. 267:483–489.PubMedCrossRefGoogle Scholar
  14. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL. et al. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS clinical trials group. N Engl J Med 334:1011–1017.Google Scholar
  15. Connor EM, Sperling RS, Gelber R, Kiselev P, et al. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol, 076 study group. NEJM. 331:1173–1180.Google Scholar
  16. Coovadia H. 2004. Antiretroviral agents – how best to protect infants from HIV and save their mothers from AIDS. N Engl J Med 351:289–292.PubMedCrossRefGoogle Scholar
  17. Cvetkovic RS, Goa KL. 2003. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 63:769–802.PubMedCrossRefGoogle Scholar
  18. DeClercq E. 2003. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev. 16: 569–596.CrossRefGoogle Scholar
  19. Deeks SJ. 2006. Antiretroviral treatment of HIV infected adults. BMJ. 332:1489–1489.PubMedCrossRefGoogle Scholar
  20. DeLuca A, DiGiambenedetto S, Maida I, Nunez M, et al. 2004. Triple nucleoside regimens versus efavirenz. NEJM. 351:717–719.CrossRefGoogle Scholar
  21. Dolin R, Amato DA, Fischl MA, Pettinelli C, et al. 1995. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trial Group. Arch Int Med. 155:961–974.Google Scholar
  22. Doyon L, Tremblay S, Bourgon L, Wardrop E, et al. 2005. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptide protease inhibitor tipranavir. Antiviral Res. 68:27–35.PubMedCrossRefGoogle Scholar
  23. Dudley MN. 1995. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis. 171:S99–S112.PubMedCrossRefGoogle Scholar
  24. Ellis JM, Ross JW, Coleman CI. 2004. Fosamprenavir: A novel protease inhibitor and prodrug of amprenavir. Formulary. 19:151–160.Google Scholar
  25. Embretson J, Zapancic M, Ribas JL, Burke A. et al. 1993. Massive convert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 362:359–362.PubMedCrossRefGoogle Scholar
  26. Fauci AS. 1996. Host factors and the pathogenesis of HIV-induced disease. Nature. 384:529–534.PubMedCrossRefGoogle Scholar
  27. Feldman C. 2005. Pneumonia associated with HIV infection. Curr Opin Infect Dis. 18:165–170.PubMedCrossRefGoogle Scholar
  28. Fischl MA, Stanley K, Collier AC, Arduino JM, et al. 1995. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials. Ann Int Med. 122:24–32.Google Scholar
  29. Flexner C. 1998. HIV-protease inhibitors. N Engl J Med. 338:1281–1292.PubMedCrossRefGoogle Scholar
  30. Flexner C. 2000. Dual protease inhibitor therapy in HIV-infected patient: Pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol. 40:649–674.PubMedCrossRefGoogle Scholar
  31. Flexner C. 2005. Antiretroviral agents and treatment of HIV infection. In: Brunton LL, Ed. Goodman and Gilman’s, the Pharmacological Basis of Therapeutics. 11th Ed., The McGraw-Hill Companies.Google Scholar
  32. Flexner C, Bate G, Kirkpatrick P. 2005. Tipranavir. Nat Rev Drug Discov. 4:955–956.PubMedCrossRefGoogle Scholar
  33. Furman PA, Fyfe JA, St. Clair MH, Weinhold K, et al. 1986. Phosphorylation of 3-azido-3 deoxythymidine and selective interaction of the 5’ triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA. 83:8333–8337.Google Scholar
  34. Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, et al. 2003. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: A clinical review of antiretroviral resistance. Antivir Ther. 8:489–506.PubMedGoogle Scholar
  35. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, et al. 2006. Tenofovir DF, Emtricitabine and Efavireuz vs. Zidovudine, Lamivudine and Efavirenz for HIV. NEJM. 354:251–260.PubMedCrossRefGoogle Scholar
  36. Gallo RC. 2005. The end or the beginning of the drive to an HIV preventive vaccine: a view from over 20 years. Lancet. 366:1894–1898.PubMedCrossRefGoogle Scholar
  37. Gao F, Bailes E, Robertson DL, Chen Y. et al. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes. Nature. 397:436–441.PubMedCrossRefGoogle Scholar
  38. Greene WC. 1991. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med. 324:308–317.PubMedCrossRefGoogle Scholar
  39. Greene WC. 1993. AIDS and the immune system. Sci Am. 269:98–105.PubMedCrossRefGoogle Scholar
  40. Greene WC, Peterlin BM. 2002. Charting HIV’s remarkable voyage through the cell: Basic science as a passport for future therapy. Nat Med. 8:673–680.PubMedCrossRefGoogle Scholar
  41. Gulick RM, Mellors JW, Havilir D, Eron JJ, et al. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. NEJM. 337:734–739.PubMedCrossRefGoogle Scholar
  42. Gulick RM, Ribaudo HJ, Shikuma CM, Lustarten S, et al. 2004. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-infection. NEJM. 350:1850–1861.PubMedCrossRefGoogle Scholar
  43. Guss DA. 1994. The acquired immune deficiency syndrome: an overview for the emergency physician, Part I. J Emerg Med. 12:375–384.PubMedCrossRefGoogle Scholar
  44. Guss DA. 1994. The acquired immune deficiency syndrome: an overview for the emergency physician, Part II. J Emerg Med 12:491–497.PubMedCrossRefGoogle Scholar
  45. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, et al. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS clinical trials group study, 175 study team. NEJM. 335:1081–10990.PubMedCrossRefGoogle Scholar
  46. Hammer SM, Saag, MS, Schechter M, Montaner JSG, et al. 2006. Treatment for adult infection: 2006. Recommendations of the International AIDS Society-USA Panel. JAMA. 296:827–843.PubMedCrossRefGoogle Scholar
  47. Heeney JL, Dalgleish AG, Weiss RA. 2006. Origins of HIV and the evolution of resistance to AIDS. Science. 313: 462–466.PubMedCrossRefGoogle Scholar
  48. Hervey PS, Perry CM. 2000. Abacavir: A review of its clinical potential in patients with HIV infection. Drugs. 60:447–479.PubMedCrossRefGoogle Scholar
  49. Ho DD, Pomerantz RJ, Kaplan JC. 1987. Pathogenesis of infection with human immunodeficiency virus. N Engl J Med. 317:278–286.PubMedCrossRefGoogle Scholar
  50. Ho DD, Neumann AU, Perelson AS, Chen W. et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV infection. Nature. 373:123–126.PubMedCrossRefGoogle Scholar
  51. Hoxie JA, Alpers JD, Rackowski JL, Huebner K. et al. 1986. Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. Science. 234:1123–1127.PubMedCrossRefGoogle Scholar
  52. Johnston MI, Fauci AS. 2007. An HIV vaccine – evolving concepts. N Engl J Med. 356: 2073–2081.PubMedCrossRefGoogle Scholar
  53. Kahn JO, Walker BD. 1998. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 331:33–39.CrossRefGoogle Scholar
  54. Kaplan SS, Hicks CB. 2005. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother. 56:273–276.PubMedCrossRefGoogle Scholar
  55. Keet IP, Krol A, Klein MR, Veugelers P. et al. 1994. Characteristics of long term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. J Infect Dis. 169:1236–1243.PubMedCrossRefGoogle Scholar
  56. Kestler H, Kodama T, Ringler D, Marthas M. et al. 1990. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science. 248:1109–1112.PubMedCrossRefGoogle Scholar
  57. King JR, Acosta EP. 2006. Tipranavir: A novel nonpeptide protease inhibitor of HIV. Clin Pharmacokinet. 45:665–682.PubMedCrossRefGoogle Scholar
  58. Kinter A, McNally J, Riggin L, Jackson R, et al. 2007. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci USA. 104:3390–3395.Google Scholar
  59. Kuritzkes DR. 2004. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDs. 18:259–273.PubMedCrossRefGoogle Scholar
  60. Laessig KA, Lewis LL, Hammerstrom TS, Jenny-Avital ER, et al. 2006. Tenofir DF and emtricitabine vs. zidovudine and lamivudine. NEJM. 354:2506–2508.PubMedCrossRefGoogle Scholar
  61. Lalezari JP, Henry K, O’Hearn M, Montaner JSG, et al. 2003. Enfuvirtide on HIV fusion inhibitor, for drug resistant HIV infection in North and South America. NEJM. 348:2175–2185.PubMedCrossRefGoogle Scholar
  62. Lawn SD. 2004. AIDS in Africa. The impact of coinfections on the pathogenesis of HIV-1 infection. J Infect Dis. 48:1–12.Google Scholar
  63. Lazzarin A, Clotet B, Cooper D, Reynes J, et al. 2003. Efficacy of enfuvirtide in patients infected with drug resistant HIV-1 in Europe and Australia. NEJM. 348:2186–2195.PubMedCrossRefGoogle Scholar
  64. Lee LM, Karon JM, Selik R, Neal JJ, et al. 2001. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States 1984–1997. JAMA, 285:1308–1315.PubMedCrossRefGoogle Scholar
  65. Letvin NL, Daniel MD, Sehgal PK, Desrosiers RC. et al. 1985. Induction of AIDS like disease in macaque monkeys with T-Cell tropic retrovirus STLV-III. Science. 230:71–73.PubMedCrossRefGoogle Scholar
  66. Levy JA. 1993. HIV pathogenesis and long term survival. AIDS. 7:1401–1410.PubMedCrossRefGoogle Scholar
  67. Levy JA. 1993. Pathogenesis of human immunodeficiency virus infection. Microbial Rev. 57:183–289.Google Scholar
  68. Lohse N, Hansen ABE, Gerstoft J, Obel N. 2007. Improved survival in HIV-infected persons: Consequences and perspectives. J Antimicrob Chemother. 60:461–463.PubMedCrossRefGoogle Scholar
  69. Luft BJ, Chua A. 2000. Central nervous system Toxoplasmosis in HIV pathogenesis, diagnosis and therapy. Curr Infect Dis Rep. 2:358–362.PubMedCrossRefGoogle Scholar
  70. MacArthur RD. 2007. Darunavir: Promising initial results. Lancet. 369:1143–1144.PubMedCrossRefGoogle Scholar
  71. Manfredi R, Sabbatani S. 2006. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr Med Chem. 13:2369–2384.PubMedGoogle Scholar
  72. Markel H. 2005. The search for effective HIV vaccines. N Engl J Med. 353:753–757.PubMedCrossRefGoogle Scholar
  73. Martin AM, Nolan D, Gaudieri S, Almeida CA, et al. 2004. Predisposition to abacavir hypersensitivity conferred by HLA-B∗57021 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA. 101:4180–4185.Google Scholar
  74. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, et al. 2003. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. NEJM. 349:1036–1046.PubMedCrossRefGoogle Scholar
  75. Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, et al. 2000. Antiretroviral resistance during successful therapy of human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA. 97:10948–10953.Google Scholar
  76. Marx JL. 1982. New disease baffles medical community. Science. 217:618–621.PubMedCrossRefGoogle Scholar
  77. McLead GX, Hammer SM. 1992. Zidovudine: Five years later. Ann Intern Med. 117:487–501.Google Scholar
  78. Mellors JW, Rinaldo CR, Gupta P, White RM, et al. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1167–1170.PubMedCrossRefGoogle Scholar
  79. Mellors JW, Munoz A, Giorgi JV, Margolick JB, et al. 1997. Plasma viral load and CD4+ lymphocytes as a prognostic markers of HIV infection. Ann Intern Med. 126:946–954.PubMedGoogle Scholar
  80. Nilsson J, Boasso A, Velilla PA, Zhang R, et al. 2006. HIV-1 driven regulatory T cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood. 108: 3808–3817.PubMedCrossRefGoogle Scholar
  81. Oldfield V, Keating GM, Plosker G. 2005. Enfuvirtide: A review of its use in the management of HIV infection. Drugs. 65:1139–1160.PubMedCrossRefGoogle Scholar
  82. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus. HIV outpatient study investigators. N Engl J Med. 338:853–860.Google Scholar
  83. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, et al. 1994. Major expansion of CD8+ T Cells with a predominant V beta usage during the primary immune response to HIV. Nature. 370:463–467.PubMedCrossRefGoogle Scholar
  84. Perelson AS, Neumann AU, Markowitz M, Leonard JM, et al. 1996. HIV-1 dynamics in vivo: Virion clearance rate, infected cell-life span, and viral generation time. Science. 271: 1582–1586.PubMedCrossRefGoogle Scholar
  85. Perry CM, Faulds D. 1997. Lamivudine: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 53:657–680.PubMedCrossRefGoogle Scholar
  86. Perry CM, Noble S. 1998. Saquinavir soft-gel formulation: A Review of its use in patients with HIV infection. Drugs. 55:461–486.PubMedCrossRefGoogle Scholar
  87. Perry CM, Noble S. 1999. Didanosine: An updated review of its use in HIV infection. Drugs. 58:1099–1135.PubMedCrossRefGoogle Scholar
  88. Piscitelli SC, Gallicano KD. 2001. Interactions among drugs for HIV and opportunistic infection. NEJM. 344:984–996.PubMedCrossRefGoogle Scholar
  89. Plosker GL, Noble S. 1999. Indinavir: A review of its use in the management of HIV infection. Drugs. 58:1165–1203.PubMedCrossRefGoogle Scholar
  90. Pollard VW, Mallim MH. 1998. The HIV-1 Rev protein. Annu Rev Microbial. 52:491–532CrossRefGoogle Scholar
  91. Popovic M, Sarngadharan MG, Read E, Gallo RC. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-111) from patients with AIDS and pre AIDS. Science. 224:497–500.PubMedCrossRefGoogle Scholar
  92. Rivero A, Mira JA, Pineda JA. 2007. Liver toxicity induced by nono-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 59:342–346.PubMedCrossRefGoogle Scholar
  93. Sataszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, et al. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team. NEJM. 341:1865–1873.Google Scholar
  94. Shafer RW, Smeaton LM, Robbins GK, Gruttola V, et al. 2003. Comparison of four drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. NEJM. 349:2304–2315.PubMedCrossRefGoogle Scholar
  95. Shankar P, Russo M, Harnisch B, Patterson M, et al. 2000. Impaired function of circulating HIV-specific CD8+ T cells in chronic human immunodeficiency virus infection. Blood. 96: 3094–3101.PubMedGoogle Scholar
  96. Spence RA, Kati WM, Anderson KS, Johnson KA. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 267:988–993.PubMedCrossRefGoogle Scholar
  97. Sperling RS, Shapirom DE, Coombsm RW, Todd JA, et al. 1996. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 335:1621–1629.PubMedCrossRefGoogle Scholar
  98. Steinbrook R. 2004. The AIDS epidemic in 2004. N Engl J Med. 351:115–117.PubMedCrossRefGoogle Scholar
  99. Swainston-Harrison T, Scott LJ. 2005. Atazanavir: A review of its use in the management of HIV infection. Drugs. 65:2309–2336.PubMedCrossRefGoogle Scholar
  100. Tonks A. 2007. Quest for the AIDS vaccine. BMJ. 334:1346–1348.PubMedCrossRefGoogle Scholar
  101. Wang JH. Janas AM, Oson WJ, Kewal Ramani VN, et al. 2007. CD4 coexpression regulates DC-SIGN-mediated transmission of human immunodeficiency virus type 1. J Virol. 81: 2497–2507.Google Scholar
  102. Watts DH, Brown ZA, Tartaglione T, Burchett SK, et al. 1991. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 163:226–232.PubMedCrossRefGoogle Scholar
  103. Wei X, Ghosh SK, Taylor ME, Johnson VA, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:117–122.PubMedCrossRefGoogle Scholar
  104. Wire MB, Shelton MJ, Studenberg S. 2006. Forsamprenavir: Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 45:137–168.PubMedCrossRefGoogle Scholar
  105. Wood E, Hogg RS, Yip B, Harrigan PR, et al. 2003. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS. 17:711–720.PubMedCrossRefGoogle Scholar
  106. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science. 280:1884–1888.PubMedCrossRefGoogle Scholar
  107. Young SD, Britcher SF, Tran LO, Payne LS, et al. 1995. Erfavirenz: A novel highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrog Agents Chemother. 39:2602–2605.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Creighton University Medical CenterOmahaUSA

Personalised recommendations